Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.

13-Dec-2011 - Switzerland

Molecular Partners AG announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin® products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins®, to address diseases where unmet needs for effective treatment options continue to exist.

Under the agreement, Molecular Partners and Janssen Biotech will collaborate on research of DARPins to selected targets.  During the research phase, Janssen Biotech has the right to exercise four options to exclusively license DARPin®-based products.  Upon execution of each option, Janssen Biotech will be solely responsible for all clinical development, manufacturing, and commercialization activities.  Molecular Partners has an option to co-develop one product on a global basis.

Molecular Partners will receive significant upfront fees, license payments and research funding as part of an innovative agreement, as well as development and sales milestones of up to $200 million for each option. Upon commercialization, Molecular Partners will be entitled to a tiered and up to double-digit royalty on worldwide net sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

Study in Spain and Romania confirms radon as second leading cause of lung cancer

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis